Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs

Executive Summary

FDA’s focus on the optimal dose for AstraZeneca’s medullary thyroid cancer treatment vandetanib could portend a harder line in ensuring that appropriate dosing for new cancer drugs is established before approval.
Advertisement

Related Content

Expanded Access Opens Window For Dose Optimization Studies In Cancer
Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients
Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications

Topics

Advertisement
UsernamePublicRestriction

Register

PS052919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel